In addition, Wülfing observed in 12 (from 17) patients with HER2-positive CTCs, the primary tumor was negative for HER2, as assessed by immunohistochemical score and fluorescence in situ hybridization [62]. This evidence concerns the gene ERBB2 and neoplasm.